SoFi Invest
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Israeli cannabis producer Intercure has applied to have its stock listed on the Nasdaq. The stock is currently listed on the Toronto Stock Exchange under the ticker symbol "INCR:U" and on the Tel Aviv Stock Exchange under the ticker symbol "INCR." If accepted, the stock will trade on the Nasdaq under the same symbol.
We'll update this page as new information becomes available.
SoFi Invest
eToro
Robinhood
Latest market close | $3.72 |
---|---|
52-week range | $3.27 - $8.20 |
50-day moving average | $4.22 |
200-day moving average | $5.26 |
Wall St. target price | $33.70 |
PE ratio | 16.3636 |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $0.22 |
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $3.72 from 2023-02-01
1 week (2023-01-26) | -0.53% |
---|---|
1 month (2022-12-30) | 12.73% |
3 months (2022-11-02) | -24.24% |
6 months (2022-08-02) | -39.61% |
1 year (2022-02-02) | -41.97% |
---|---|
2 years (2021-02-02) | 118.82% |
3 years (2020-01-30) | 200.00% |
5 years (2018-01-29) | N/A |
Valuing Intercure stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Intercure's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Intercure's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 16x. In other words, Intercure shares trade at around 16x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
However, Intercure's P/E ratio is best considered in relation to those of others within the drug manufacturers-specialty & generic industry or those of similar companies.
Gross profit TTM | $102.6 million |
---|---|
Return on assets TTM | 5.38% |
Return on equity TTM | 7.36% |
Profit margin | 9.15% |
Book value | N/A |
Market capitalisation | $164.1 million |
TTM: trailing 12 months
We're not expecting Intercure to pay a dividend over the next 12 months.
Intercure's shares were split on a 946:4209 basis on 8 April 2021. So if you had owned 4209 shares the day before before the split, the next day you'd have owned 946 shares. This wouldn't directly have changed the overall worth of your Intercure shares – just the quantity. However, indirectly, the new 344.9% higher share price could have impacted the market appetite for Intercure shares which in turn could have impacted Intercure's share price.
Over the last 12 months, Intercure's shares have ranged in value from as little as $3.27 up to $8.2. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Intercure's is -0.2095. This would suggest that Intercure's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Intercure has bucked the trend.
To put Intercure's beta into context you can compare it against those of similar companies.
InterCure Ltd. , together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally. It offers dried cannabis inflorescences and cannabis extract mixed with oil. The company also invests in biomed sector. InterCure Ltd. was incorporated in 1994 and is headquartered in Herzliya, Israel. .
Everything we know about the Neuraxis IPO, plus information on how to buy in.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.